Litcius/Paper detail

Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma

Oliver Kennedy, Michal Kiciński, Sara Valpione, Sara Gandini, Stefan Suciu, Christian U. Blank, Georgina V. Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Marye J. Boers‐Sonderen, Anna Maria Di Giacomo, Alfonsus Johannes Maria van den Eertwegh, Jean‐Jacques Grob, Ralf Gutzmer, Rahima Jamal, Alexander C. J. van Akkooi, Caroline Robert, Alexander M.M. Eggermont, Paul Lorigan, Mario Mandalà

2023European Journal of Cancer19 citationsDOIOpen Access PDF

Topics & Concepts

PembrolizumabMedicineMetforminPlaceboStage (stratigraphy)Internal medicineOncologyPredictive valueCancerPhases of clinical researchClinical trialImmunotherapyPathologyAlternative medicineInsulinBiologyPaleontologyMetabolism, Diabetes, and CancerCancer Risks and FactorsDiabetes Treatment and Management
Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma | Litcius